C9311 HCPCS code: Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
C9311 is the HCPCS Level II code for injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered). Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2026-10-01 |
| Last action effective | 2026-10-01 |
What changed for C9311
- October 2026: Code appears in this HCPCS release
- 2026-10-01: C9311 added to HCPCS Level II
- 2026-10-01: Last CMS action: code added
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9311?
C9311 is the HCPCS Level II code for injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered). Short descriptor: "Inj, eplontersen, 1 mg".
Does Medicare cover C9311?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Related C93 codes
- C9300 — Injection, indigotindisulfonate sodium, 1 mg
- C9301 — Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9302 — Injection, zanidatamab-hrii, 2 mg
- C9303 — Injection, zolbetuximab-clzb, 1 mg
- C9304 — Injection, marstacimab-hncq, 0.5 mg
- C9305 — Injection, nipocalimab-aahu, 3 mg
- C9306 — Injection, telisotuzumab vedotin-tllv, 1 mg
- C9307 — Injection, linvoseltamab-gcpt, 1 mg
- C9308 — Injection, carboplatin (avyxa), 1 mg
- C9309 — Injection, onasemnogene abeparvovec-brve, per treatment
- C9310 — Injection, leucovorin calcium (avyxa), 1 mg
- C9312 — Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9311
- Watch C9311 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9311
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.